These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 32048563)

  • 1. Practice variation on hospital level in the systemic treatment of metastatic colorectal cancer in The Netherlands: a population-based study.
    Keikes L; Koopman M; Stuiver MM; Lemmens VEPP; van Oijen MGH; Punt CJA
    Acta Oncol; 2020 Apr; 59(4):395-403. PubMed ID: 32048563
    [No Abstract]   [Full Text] [Related]  

  • 2. Sidedness and TP53 mutations impact OS in anti-EGFR but not anti-VEGF treated mCRC - an analysis of the KRAS registry of the AGMT (Arbeitsgemeinschaft Medikamentöse Tumortherapie).
    Huemer F; Thaler J; Piringer G; Hackl H; Pleyer L; Hufnagl C; Weiss L; Greil R
    BMC Cancer; 2018 Jan; 18(1):11. PubMed ID: 29298682
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of Primary Tumor Site With Mortality in Patients Receiving Bevacizumab and Cetuximab for Metastatic Colorectal Cancer.
    Aljehani MA; Morgan JW; Guthrie LA; Jabo B; Ramadan M; Bahjri K; Lum SS; Selleck M; Reeves ME; Garberoglio C; Senthil M
    JAMA Surg; 2018 Jan; 153(1):60-67. PubMed ID: 28975237
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metastatic colorectal cancer treatment patterns according to kirsten rat sarcoma viral oncogene homolog genotype in U.S. Community-based oncology practices.
    Landsman-Blumberg PB; Carter GC; Johnson BH; Sedgley R; Nicol SJ; Li L; Shankaran V
    Clin Colorectal Cancer; 2014 Sep; 13(3):178-84. PubMed ID: 25065655
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of Guideline Adherence in Colorectal Cancer Treatment in The Netherlands: A Survey Among Medical Oncologists by the Dutch Colorectal Cancer Group.
    Keikes L; van Oijen MGH; Lemmens VEPP; Koopman M; Punt CJA
    Clin Colorectal Cancer; 2018 Mar; 17(1):58-64. PubMed ID: 29157662
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Practice Patterns in Chemotherapeutic Treatment Regimens for Metastatic Colorectal Cancer.
    McLean J; Rho YS; Kuruba G; Mamo A; Gilabert M; Kavan T; Panasci L; Melnychuk D; Batist G; Kavan P
    Clin Colorectal Cancer; 2016 Jun; 15(2):135-40. PubMed ID: 26553578
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Survival improvements associated with access to biological agents: Results from the South Australian (SA) metastatic colorectal cancer (mCRC) registry.
    Tomita Y; Karapetis CS; Ullah S; Townsend AR; Roder D; Beeke C; Roy AC; Padbury R; Price TJ
    Acta Oncol; 2016; 55(4):480-5. PubMed ID: 26878155
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Upfront resection versus no resection of the primary tumor in patients with synchronous metastatic colorectal cancer: the randomized phase III CAIRO4 study conducted by the Dutch Colorectal Cancer Group and the Danish Colorectal Cancer Group.
    van der Kruijssen DEW; Elias SG; van de Ven PM; van Rooijen KL; Lam-Boer J'; Mol L; Punt CJA; Sommeijer DW; Tanis PJ; Nielsen JD; Yilmaz MK; van Riel JMGH; Wasowiz-Kemps DK; Loosveld OJL; van der Schelling GP; de Groot JWB; van Westreenen HL; Jakobsen HL; Fromm AL; Hamberg P; Verseveld M; Jaensch C; Liposits GI; van Duijvendijk P; Oulad Hadj J; van der Hoeven JAB; Trajkovic M; de Wilt JHW; Koopman M;
    Ann Oncol; 2024 Sep; 35(9):769-779. PubMed ID: 38852675
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The clinical benefit of bevacizumab in metastatic colorectal cancer is independent of K-ras mutation status: analysis of a phase III study of bevacizumab with chemotherapy in previously untreated metastatic colorectal cancer.
    Hurwitz HI; Yi J; Ince W; Novotny WF; Rosen O
    Oncologist; 2009 Jan; 14(1):22-8. PubMed ID: 19144677
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic importance of tumor location and anti-EGFR therapy in patients with K-RAS wild type metastatic colorectal cancer.
    Kucukoner M; Oztekin E; Akdeniz N; Morkuzu S; Yerlikaya H; Urakci Z; Kaplan MA; Isikdogan A
    J BUON; 2019; 24(4):1501-1506. PubMed ID: 31646798
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic significance of K-Ras mutation rate in metastatic colorectal cancer patients.
    Vincenzi B; Cremolini C; Sartore-Bianchi A; Russo A; Mannavola F; Perrone G; Pantano F; Loupakis F; Rossini D; Ongaro E; Bonazzina E; Dell'Aquila E; Imperatori M; Zoccoli A; Bronte G; De Maglio G; Fontanini G; Natoli C; Falcone A; Santini D; Onetti-Muda A; Siena S; Tonini G; Aprile G
    Oncotarget; 2015 Oct; 6(31):31604-12. PubMed ID: 26384309
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RAS mutation testing in patients with metastatic colorectal cancer in French clinical practice: A status report in 2014.
    Lièvre A; Merlin JL; Sabourin JC; Artru P; Tong S; Libert L; Audhuy F; Gicquel C; Moureau-Zabotto L; Ossendza RA; Laurent-Puig P; Ducreux M
    Dig Liver Dis; 2018 May; 50(5):507-512. PubMed ID: 29396127
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimization of
    Santos C; Azuara D; Garcia-Carbonero R; Alfonso PG; Carrato A; Elez ME; Gomez A; Losa F; Montagut C; Massuti B; Navarro V; Varela M; Lopez-Doriga A; Moreno V; Valladares M; Manzano JL; Vieitez JM; Aranda E; Sanjuan X; Tabernero J; Capella G; Salazar R
    Mol Cancer Ther; 2017 Sep; 16(9):1999-2007. PubMed ID: 28626084
    [TBL] [Abstract][Full Text] [Related]  

  • 14. First-line treatment choices of Turkish medical oncologists in metastatic colorectal cancer: A survey study.
    Beypinar I; Araz M; Uysal M; Yalcin S
    J BUON; 2019; 24(1):68-76. PubMed ID: 30941953
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population-based study on practice variation regarding preoperative systemic chemotherapy in patients with colorectal liver metastases and impact on short-term outcomes.
    Elfrink AKE; Kok NFM; van der Werf LR; Krul MF; Marra E; Wouters MWJM; Verhoef C; Kuhlmann KFD; den Dulk M; Swijnenburg RJ; Te Riele WW; van den Boezem PB; Leclercq WKG; Lips DJ; Nieuwenhuijs VB; Gobardhan PD; Hartgrink HH; Buis CI; Grünhagen DJ; Klaase JM; ;
    Eur J Surg Oncol; 2020 Sep; 46(9):1742-1755. PubMed ID: 32303416
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bevacizumab for metachronous metastatic colorectal cancer: a reflection of community based practice.
    Razenberg LG; van Gestel YR; de Hingh IH; Loosveld OJ; Vreugdenhil G; Beerepoot LV; Creemers GJ; Lemmens VE
    BMC Cancer; 2016 Feb; 16():110. PubMed ID: 26882902
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Continuation of Bevacizumab vs Cetuximab Plus Chemotherapy After First Progression in KRAS Wild-Type Metastatic Colorectal Cancer: The UNICANCER PRODIGE18 Randomized Clinical Trial.
    Bennouna J; Hiret S; Bertaut A; Bouché O; Deplanque G; Borel C; François E; Conroy T; Ghiringhelli F; des Guetz G; Seitz JF; Artru P; Hebbar M; Stanbury T; Denis MG; Adenis A; Borg C
    JAMA Oncol; 2019 Jan; 5(1):83-90. PubMed ID: 30422156
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence of RAS mutations and individual variation patterns among patients with metastatic colorectal cancer: A pooled analysis of randomised controlled trials.
    Peeters M; Kafatos G; Taylor A; Gastanaga VM; Oliner KS; Hechmati G; Terwey JH; van Krieken JH
    Eur J Cancer; 2015 Sep; 51(13):1704-13. PubMed ID: 26049686
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A polymorphism within the R-spondin 2 gene predicts outcome in metastatic colorectal cancer patients treated with FOLFIRI/bevacizumab: data from FIRE-3 and TRIBE trials.
    Berger MD; Ning Y; Stintzing S; Heinemann V; Cao S; Zhang W; Yang D; Miyamoto Y; Suenaga M; Schirripa M; Hanna DL; Soni S; Puccini A; Tokunaga R; Naseem M; Battaglin F; Cremolini C; Falcone A; Loupakis F; Lenz HJ
    Eur J Cancer; 2020 May; 131():89-97. PubMed ID: 32305727
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A study-level meta-analysis of efficacy data from head-to-head first-line trials of epidermal growth factor receptor inhibitors versus bevacizumab in patients with RAS wild-type metastatic colorectal cancer.
    Heinemann V; Rivera F; O'Neil BH; Stintzing S; Koukakis R; Terwey JH; Douillard JY
    Eur J Cancer; 2016 Nov; 67():11-20. PubMed ID: 27592068
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.